Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061913 | 0.97 | — | — | |
| SCHEMBL31194974 | 0.90 | POLB (0.41) | ALDH1A1TSHRHRH3CARM1PRMT6 | |
| SCHEMBL31194969 | 0.90 | POLB (0.41) | ALDH1A1TSHRHRH3CARM1PRMT6 | |
| SCHEMBL31194972 | 0.86 | ALOX15 (0.38) | ALDH1A1TSHRCARM1PRMT6PRMT8 | |
| SCHEMBL17209067 | 0.85 | HRH3 (0.56) | ALDH1A1TSHRHRH3CARM1PRMT6 | |
| SCHEMBL18520145 | 0.82 | HRH3 (0.52) | ALDH1A1TSHRHRH3CARM1PRMT6 | |
| SCHEMBL24160080 | 0.81 | HRH3 (0.65) | ALDH1A1TSHRHRH3ALOX15MAPT | |
| SCHEMBL16943890 | 0.79 | PAOX (0.38) | ALOX15CYP1A2LMNASIGMAR1 | |
| SCHEMBL19969485 | 0.78 | HTR1A (0.38) | ALDH1A1TSHRALOX15CYP1A2 | |
| SCHEMBL4173915 | 0.78 | HRH3 (0.52) | ALDH1A1TSHRHRH3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230161252-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230161252-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230161255-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3643717-B1 | 7-SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREFOR AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-20150203526-A1 | NOVEL 19-NOR-STEROIDS AND THEIR USE FOR TREATING PROGESTERONE- DEPENDENT CONDITIONS | REPROS THERAPEUTICS INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-20130274234-A1 | NOVEL 19-NOR-STEROIDS AND THEIR USE FOR TREATING PROGESTERONE- DEPENDENT CONDITIONS | REPROS THERAPEUTICS INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130018027-A1 | COMPOSITIONS AND METHODS FOR NON-TOXIC DELIVERY OF ANTIPROGESTINS | REPROS THERAPEUTICS INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6639109-B1 | Reacting amino alcohol with sulfuric acid then reacting resulting amino sulfate with a mercaptan; simple, safe, rapid | NIHON NOHYAKU CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1216988-A1 | THIOALKYLAMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203526-A1 | NOVEL 19-NOR-STEROIDS AND THEIR USE FOR TREATING PROGESTERONE- DEPENDENT CONDITIONS | HSD17B11, CYP19A1, ESRRB | ALDH1A1 672/4885TSHR 288/4885HRH3 2909/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | ALDH1A1 1802/4885TSHR 274/4885HRH3 141/4885 |
| US-20130018027-A1 | COMPOSITIONS AND METHODS FOR NON-TOXIC DELIVERY OF ANTIPROGESTINS | PGF, CYP19A1, GNRHR | ALDH1A1 1319/4885TSHR 285/4885HRH3 2358/4885 |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | ALDH1A1 4006/4885TSHR 2262/4885HRH3 1656/4885 |
| US-20130274234-A1 | NOVEL 19-NOR-STEROIDS AND THEIR USE FOR TREATING PROGESTERONE- DEPENDENT CONDITIONS | HSD17B11, CYP19A1, ESRRB | ALDH1A1 672/4885TSHR 288/4885HRH3 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.